Record Revenue and Margin Performance
PHOENIX, Nov. 12,
2024 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:
SNES, "SenesTech" or the "Company"), the leader in fertility
control to manage animal pest populations and the only manufacturer
of commercial and consumer available EPA-registered Rat Birth
Control® products today announced financial results for
the third quarter of 2024.
Recent Highlights
- Revenues of $1.4 million in the
first nine months of 2024, an increase of 51% compared to the same
period of 2023.
- Gross margin percentages improved to 65% during Q3 2024
compared to 49% in Q3 2023 driven by improvements in manufacturing
operations and scale. Gross profit dollars increased 79% during Q3
2024 compared to Q3 2023.
- Operating expenses decreased 12% in Q3 2024 compared to Q3 2023
as the Company maintains tight control of expenses.
- Quarterly adjusted EBITDA loss is the smallest in the Company's
history, cutting the cash burn by 21% compared to the year ago
quarter, as the Company focuses on its near-term goal of breaking
even.
Updates on Key Growth Initiatives
- Launch of EvolveTM Rat: The Evolve Rat product,
formulated especially for the proactive control of rodent fertility
and launched at the beginning of 2024, has quickly become the
Company's biggest-selling product line, contributing approximately
52% of Q3 2024 revenue. Q3 2024 sales of Evolve Rat increased 11%
compared to Q2 2024.
- Launch of EvolveTM Mouse: The Evolve Mouse product,
a fertility solution to proactively control mouse infestations,
utilizing the same revolutionary breakthrough technology as the rat
solution, was launched in May 2024
and quickly contributed 17% of Q3 2024 revenue.
- Expansion with key online retailers: The Company successfully
launched Evolve Rat and Evolve Mouse on Amazon and
diypestcontrol.com during the first half of 2024. Amazon
represented 43% of overall e-commerce sales in the third quarter.
Last week, the Company began selling product on Walmart.com and
received approval from TractorSupply.com with product expected to
be available for purchase in the coming weeks. Overall, sales on
e-commerce related platforms, including SenesTech.com continue to
trend upwards, with sales increasing approximately 20% in Q3 2024
compared to Q3 2023 representing approximately 35% of YTD 2024
sales.
- Brick and mortar retail chain adoption: The Company has
increased its adoption of Evolve within its first key national home
improvement retailer. The Company is also working with five
manufacturer's representative agencies, with more than 50 outside
representatives, targeting retail, coop and big box chains to
inventory Evolve in their stores. The Company expects decisions
from multiple retailers for store placement before the end of the
year.
- Municipal programs: New York City Council has approved a bill
to implement a rat contraception pilot program. From the bill, the
term "rat contraceptive" means an agent for the reduction of
reproductive capacity in rats that is approved for such use by the
United States Environment Protection Agency and is available for
sale. SenesTech is currently the only manufacturer of products that
meet these requirements. Responding to requests from the city, the
Company has prepared and presented an initial supply proposal and
is in the process of negotiations with the city.
- International opportunities: Evolve has been registered in
Hong Kong, and the Company is
expecting pallet or container orders during the fourth quarter as
marketing and sales in Hong Kong
accelerates. In addition, the Company's distributor in The Netherlands has submitted a multi-pallet
order, the largest order in the history of the company, for
immediate fulfillment. We are also in the final stages of selecting
exclusive distributors in India,
Pakistan, Chile, Brazil
and Taiwan. Finally, the Company's
distributor in Australia/New
Zealand is in the final stages of registration for the
regulatory approval of Evolve.
- Expanded distribution agreements: We have added Site One
Supply, a pest management distributor with over 322 locations, and
Clearview, a leading agricultural distributor that services the egg
and poultry production market. With both, we are on-boarding our
products onto their system and beginning training.
- Enhanced packaging options: The Company launched new product
packaging for Evolve including convenient 1.5 pound, 3 pound, and 6
pound pouches which use 87% less plastic than traditional pails and
provide for enhanced gross margins.
- Studies: The Company currently has field efficacy trials under
way, including an east coast agricultural firm involved in sugar
cane operations and a leading pest management professional
deploying Evolve in a housing area on a west coast university
campus. In addition, a western university is completing a
laboratory efficacy trial for Evolve Mouse. Finally, a leading pest
control firm is conducting a California Department of Pesticide
Regulation funded study on sustainable alternatives to rodenticide
use.
Management Discussion
"We remain keenly focused on the rapid, multi-channel expansion
of the Evolve product line which culminated in yet another quarter
of record revenues," commented Joel
Fruendt, President and CEO of SenesTech. " From an
operational perspective, we are focused on enhanced efficiencies in
all aspects of our processes, which resulted in a new all-time
quarterly record for gross margins of 65%, and 12% year-over-year
reduction in operating expenses."
"As we finish 2024, we have a number of initiatives set to be
significant contributors to top line growth, including the recent
approval to sell Evolve on third party e-commerce platforms;
multiple large international orders set to ship before the end of
the year; adoption by key brick-and-mortar retailers; potential
deployment in New York City and
other key municipalities; and broader adoption of our new Evolve
Rat and Mouse solutions through existing channels."
"As the only manufacturer of products registered or designated
by the U.S. EPA for the restriction of rodent reproduction, we have
a tremendous opportunity ahead of us to 'Change the Game' of how
the rodent control industry addresses rodent infestations.
With Evolve, and its improved form factor, economical price point,
proven efficacy, and lengthy shelf life, we have addressed all the
key product attribute requirements communicated to us by the
industry. We look forward to continued rapid adoption of our
innovative solutions," Fruendt concluded.
Use of Non-GAAP Measure
Adjusted EBITDA is a non-GAAP measure. However, this measure is
not intended to substitute for those financial measures reported in
accordance with GAAP. Adjusted EBITDA has been included because
management believes that, when considered together with the GAAP
figures, it provides meaningful information related to our
operating performance and liquidity and can enhance an overall
understanding of financial results and trends. Adjusted EBITDA may
be calculated by us differently than other companies that disclose
measures with the same or similar term. See our attached financials
for a reconciliation of this non-GAAP measure to the nearest GAAP
measure.
Conference Call Details
Date and Time: Tuesday,
November 12, 2024, at 5:00 pm
ET
Call-in Information: Interested
parties can access the conference call by dialing (844) 308-3351 or
(412) 317-5407.
Live Webcast Information: Interested
parties can access the conference call via a live webcast, which is
available in the Investor Relations section of the Company's
website at https://app.webinar.net/B3g7axqE1nv or
http://senestech.investorroom.com/.
Replay: A teleconference replay of
the call will be available for seven days at (877) 344-7529 or
(412) 317-0088, replay access code 2809220. A webcast replay will
be available in the Investor Relations section of the Company's
website at http://senestech.investorroom.com/ for 90 days.
About SenesTech
We are committed to improving the health of the world by
humanely managing animal pest populations through our expertise in
fertility control. We invented ContraPest, the only U.S.
EPA-registered contraceptive for male and female rats, as well as
Evolve and Evolve Mouse, EPA-designated minimum risk contraceptives
for rodents, reflecting our mission to provide products that are
proactive, safe and sustainable. ContraPest and Evolve fit
seamlessly into all integrated pest management programs,
significantly improving the overall goal of effective pest
management. We strive for clean cities, efficient businesses and
happy households – with a product designed to be humane, effective
and sustainable.
For more information visit https://senestech.com/.
Safe Harbor Statement
This press release contains "forward-looking statements" within
the meaning of federal securities laws, and we intend that such
forward-looking statements be subject to the safe harbor created
thereby. Such forward-looking statements include, among others, our
expectation that second half growth will be driven by key growth
initiatives implemented in the first half of 2024, to include: (i)
the launch of Evolve with key online retailers, including
Amazon.com and diypestcontrol.com, (ii) the launch of Evolve Mouse
in May 2024, a fertility solution to
proactively control mouse infestations, utilizing the same
revolutionary breakthrough technology as the rat solution, (iii)
the ramp up of recently secured distribution agreements with
leading agricultural and pest management industry distributors,
(iv) the new product packaging introduced to include convenient 1.5
pound, 3 pound, and 6 pound pouches, using 87% less plastic than
traditional pails, (v) the expanded sales and marketing efforts in
partnering with five manufacturer's representative agencies, with
over 50 representatives targeting 23 retail and industrial
accounts, and (vi) the expansion of the Evolve product line into
distribution and consumer-friendly channels and verticals has
opened an additional $300 million in
addressable markets; our belief that we are ideally positioned to
see accelerating growth due to the initiatives we put in place
throughout the first half of 2024, including (i) the launch of
Evolve for rats with key online retailers (ii) the launch of our
new Evolve Mouse solution, (iii) the ramp up of recently secured
distribution agreements, (iv) new product packing options, and (v)
perhaps most important, the potential adoption of Evolve by some of
the nation's largest brick-and-mortar retailers with whom we have
recently engaged over the past quarter; our belief that placement
by one or two of these retailers could result in our immediate
transition to profitability; our belief that the accelerating
revenue growth, coupled with improving gross margins and
disciplined operating expense management, will bring cash flow
breakeven within near term quarters; our belief that the game for
SenesTech and the rodent control industry has truly changed with
our Evolve soft bait solution; our belief that due to the Evolve
soft bait solution's improved form factor, economical price point,
effective efficacy, and lengthy shelf life, we finally have a
solution that is demanded by the professional pest control market
and do-it-yourselfers through online and brick-and-mortar
retailers; our optimism about the future given the progress we have
made to bring the much needed fertility control solutions to the
rodent industry.
Forward-looking statements may describe future expectations,
plans, results, or strategies and are often, but not always, made
through the use of words such as "believe," "may," "future,"
"plan," "will," "should," "expect," "anticipate," "eventually,"
"project," "estimate," "continuing," "intend" and similar words or
phrases. You are cautioned that such statements are subject to
risks, uncertainties and other factors that could cause actual
results to differ materially from those reflected by such
forward-looking statements. Such factors include, among others, the
successful commercialization of our products; market acceptance of
our products; our financial performance, including our ability to
fund operations; our ability to regain and maintain compliance with
Nasdaq's continued listing requirements; regulatory approval and
regulation of our products; and other factors and risks identified
from time to time in our filings with the Securities and Exchange
Commission, including our Annual Report on Form 10-K for the fiscal
year ended December 31, 2023. All
forward-looking statements contained in this press release speak
only as of the date on which they were made and are based on
management's assumptions and estimates as of such date. Except as
required by law, we do not undertake any obligation to publicly
update any forward-looking statements, whether as a result of the
receipt of new information, the occurrence of future events or
otherwise.
CONTACT:
Investors: Robert Blum, Lytham
Partners, LLC, (602)
889-9700, senestech@lythampartners.com
Company: Tom Chesterman, Chief
Financial Officer, SenesTech, Inc., (928) 779-4143
SENESTECH,
INC.
BALANCE
SHEETS
(In thousands, except
share and per share data)
(Unaudited)
|
|
|
September
30,
2024
|
|
December 31,
2023
|
ASSETS
|
|
|
|
Current
assets:
|
|
|
|
Cash and cash
equivalents
|
$
2,518
|
|
$
5,395
|
Accounts receivable,
net
|
214
|
|
95
|
Prepaid expenses and
other current assets
|
360
|
|
388
|
Inventory,
net
|
880
|
|
795
|
Total current
assets
|
3,972
|
|
6,673
|
Right to use assets,
operating leases
|
39
|
|
210
|
Property and equipment,
net
|
380
|
|
388
|
Other noncurrent
assets
|
58
|
|
22
|
Total
assets
|
$
4,449
|
|
$
7,293
|
|
|
|
|
LIABILITIES AND
STOCKHOLDERS' EQUITY
|
|
|
|
Current
liabilities:
|
|
|
|
Accounts
payable
|
$
128
|
|
$
150
|
Accrued
expenses
|
394
|
|
368
|
Current portion of
operating lease liability
|
41
|
|
217
|
Current portion of
notes payable
|
53
|
|
33
|
Deferred
revenue
|
12
|
|
18
|
Total current
liabilities
|
628
|
|
786
|
Notes payable, less
current portion
|
170
|
|
156
|
Total
liabilities
|
798
|
|
942
|
Stockholders'
equity:
|
|
|
|
Common
stock
|
1
|
|
1
|
Additional paid-in
capital
|
138,492
|
|
136,263
|
Accumulated
deficit
|
(134,842)
|
|
(129,913)
|
Total stockholders'
equity
|
3,651
|
|
6,351
|
Total liabilities and
stockholders' equity
|
$
4,449
|
|
$
7,293
|
SENESTECH,
INC.
STATEMENTS OF
OPERATIONS
(In thousands, except
share and per share data)
(Unaudited)
|
|
|
Three Months
Ended
September 30,
|
|
Nine Months
Ended
September 30,
|
|
2024
|
|
2023
|
|
2024
|
|
2023
|
Revenues,
net
|
$
482
|
|
$
360
|
|
$
1,356
|
|
$
898
|
Cost of
sales
|
167
|
|
184
|
|
657
|
|
488
|
Gross
profit
|
315
|
|
176
|
|
699
|
|
410
|
Operating
expenses:
|
|
|
|
|
|
|
|
Research and
development
|
451
|
|
379
|
|
1,288
|
|
1,147
|
Selling, general and
administrative
|
1,411
|
|
1,748
|
|
4,403
|
|
5,259
|
Total operating
expenses
|
1,862
|
|
2,127
|
|
5,691
|
|
6,406
|
Loss from
operations
|
(1,547)
|
|
(1,951)
|
|
(4,992)
|
|
(5,996)
|
Other income,
net
|
34
|
|
4
|
|
63
|
|
19
|
Net loss
|
$
(1,513)
|
|
$
(1,947)
|
|
$
(4,929)
|
|
$
(5,977)
|
Weighted average shares
outstanding — basic and diluted
|
729,400
|
|
34,805
|
|
586,628
|
|
25,315
|
Loss per share — basic
and diluted
|
$
(2.07)
|
|
$
(55.93)
|
|
$
(8.40)
|
|
$
(236.10)
|
SENESTECH,
INC.
Itemized
Reconciliation Between Net Loss and Adjusted EBITDA
(non-GAAP)
(In
thousands)
(Unaudited)
|
|
|
Three Months
Ended
September 30,
|
|
Nine Months
Ended
September 30,
|
|
2024
|
|
2023
|
|
2024
|
|
2023
|
Net loss (as reported,
GAAP)
|
$
(1,513)
|
|
$
(1,947)
|
|
$
(4,929)
|
|
$
(5,977)
|
Non-GAAP
adjustments:
|
|
|
|
|
|
|
|
Interest income,
net
|
(5)
|
|
(4)
|
|
(33)
|
|
(19)
|
Stock-based
compensation expense
|
73
|
|
131
|
|
246
|
|
467
|
Severance
costs
|
13
|
|
—
|
|
13
|
|
120
|
Depreciation
expense
|
42
|
|
33
|
|
115
|
|
104
|
Gain on sale of
property and equipment
|
(28)
|
|
—
|
|
(28)
|
|
—
|
Total non-GAAP
adjustments
|
95
|
|
160
|
|
313
|
|
672
|
Adjusted EBITDA loss
(non-GAAP)
|
$
(1,418)
|
|
$
(1,787)
|
|
$
(4,616)
|
|
$
(5,305)
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/senestech-announces-third-quarter-2024-financial-results-302303118.html
SOURCE SenesTech, Inc.